Cumulus News

NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder

Cumulus — Thu, 28 May 2026 08:00:00 GMT

Delix Therapeutics presented data for their novel neuroplastogen zalsupindole (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference including NeuLogiq® Platform data which supports at-home administration in future trials.

First Published: 28 May, 2026

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.

Cumulus — Tue, 10 Feb 2026 09:00:00 GMT

First Published: 10 February, 2026

Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair

Cumulus — Thu, 08 Jan 2026 09:00:00 GMT

First Published: 8 January, 2026

Cumulus Neuroscience Publishes Data Validating a Scalable Measurement of Neuroplasticity Using Low-Burden Dry Sensor EEG

Cumulus — Tue, 06 Jan 2026 09:00:00 GMT

Data published in Scientific Reports confirms a low-burden visual evoked potential (VEP) assessment can be employed across multiple clinical trial sites as an objective measure of neuroplastic modulation in real-world clinical trials of CNS therapies.

First Published: 6 February, 2026

Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting

Cumulus — Thu, 04 Dec 2025 09:00:00 GMT

Data presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting demonstrated that at-home digital endpoints show superior sensitivity to progression in Alzheimer’s Disease with potential to reduce costs and patient burden in clinical trials.

First Published: 4 December, 2025

Cumulus Neuroscience to Present Data at Clinical Trials on Alzheimer’s Disease 2025 Annual Meeting

Cumulus — Tue, 25 Nov 2025 09:00:00 GMT

Poster and Showcase Presentation accepted by the Clinical Trials on Alzheimer’s Disease (CTAD) Scientific Committee.

Data to be presented will highlight the utility of the NeuLogiq® Platform for remote, frequent data collection in Alzheimer's disease clinical trials.

First Published: 25 November, 2025

Cumulus Neuroscience Presents Data at the ISCTM Autumn Conference and the 38th ECNP Annual Congress 2025

Cumulus — Mon, 13 Oct 2025 08:00:00 GMT

First Published: 13 October, 2025

Cumulus Neuroscience to Present Data at the ISCTM Autumn Conference and the 38th ECNP Annual Meeting

Cumulus — Fri, 03 Oct 2025 08:00:00 GMT

Poster presentations to take place at ISCTM on Friday October 10th and at ECNP on Saturday October 11th in Amsterdam, the Netherlands.

First Published: 13 October, 2025

Cumulus Neuroscience Appoints Robert Ballantine to Board of Directors

Cumulus — Wed, 10 Sep 2025 08:00:00 GMT

First Published: 10 September, 2026

3-minute EEG Test Reliably Detects Memory Impairment, Enabling Earlier Alzheimer's Diagnosis

Cumulus — Tue, 02 Sep 2025 08:00:00 GMT

Breakthrough research from the University of Bath and the University of Bristol that demonstrates the real-world efficacy of a passive EEG test in identifying memory decline years before a clinical diagnosis, is being developed as a screening tool by Cumulus Neuroscience

First Published: 2 September, 2026